Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of ...

Alzheimer's disease

Health

Life Sciences

Branches of biology

Biogen

Amyloid beta

Apolipoprotein E

Eisai

Amyloid-related imaging abnormalities

Mild cognitive impairment

Clinical trial

Bapineuzumab

Eisai Inc.

United States

Biogen Inc.

u.s. food and drug administration

Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of .... View article details on HISWAI: https://www.prnewswire.com/news-releases/eisai-submits-supplemental-biologics-license-application-to-fda-for-traditional-approval-of-leqembi-lecanemab-irmb-for-the-treatment-of-alzheimers-disease-301715905.html